Jazz Pharmaceuticals (JAZZ) Other Non Operating Income (2010 - 2026)

Jazz Pharmaceuticals' Other Non Operating Income history runs 16 years deep, the most recent figure standing at $2.5 million for Q1 2026.

• In Q1 2026, Other Non Operating Income rose 1350.0% year-over-year to $2.5 million; the TTM figure through Mar 2026 stood at $145000.0 (up 102.17% YoY), while the FY2025 annual figure was -$2.6 million, up 68.61% from the prior year.
• Other Non Operating Income for Q1 2026 stood at $2.5 million, up from -$658000.0 in the prior quarter.
• The five-year high for Other Non Operating Income was $9.4 million in Q4 2023, with the low at -$10.5 million in Q1 2022.
• The 5-year median for Other Non Operating Income is -$1.3 million (2022), against an average of -$1.1 million.
• The sharpest annual moves came in 2022 and 2026: Other Non Operating Income sank 1217.71% in 2022, then soared 1350.0% in 2026.
• Jazz Pharmaceuticals' Other Non Operating Income stood at -$2.5 million in 2022, then jumped by 476.83% to $9.4 million in 2023, then sank by 167.3% to -$6.3 million in 2024, then soared by 89.55% to -$658000.0 in 2025, then surged by 479.94% to $2.5 million in 2026.
• Business Quant data shows JAZZ's Other Non Operating Income at $2.5 million in Q1 2026, -$658000.0 in Q4 2025, and $102000.0 in Q3 2025.